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OBJECTIVE — This study analyzed data from the Epidemiology of Diabetes Interventions
and Complications (EDIC) study to see whether longer-term follow-up of Diabetes Control and
ComplicationsTrial(DCCT)patientsrevealsaroleforglycemicinstabilityinthedevelopmentof
microvascular complications.
RESEARCH DESIGN AND METHODS — The mean area under the curve glucose and
the within-day glucose variability (SD and mean amplitude of glycemic excursions [MAGE])
during the DCCT were assessed to see whether they contributed to the risk of retinopathy and
nephropathy by year 4 of the EDIC.
RESULTS — Logistic regression analysis showed that mean glucose during the DCCT and
mean A1C during EDIC were independently predictive of retinopathy (each P  0.001) as well
as A1C during EDIC of nephropathy (P  0.001) development by EDIC year 4. Glucose
variability did not add to this (all P  0.25 using SD or MAGE).
CONCLUSIONS — Glucose variability in the DCCT did not predict the development of
retinopathy or nephropathy by EDIC year 4.
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A
nalysis of the Diabetes Control and
Complications Trial (DCCT) data-
set has shown that glucose variabil-
ity did not appear to be a further factor in
the development or progression of either
retinopathy or nephropathy (1,2). More
recently,variabilityinA1C,alonger-term
marker of glycemic control, during the
DCCT has been found to add to the risk
already indicated by the mean A1C
value (3).
This current study has examined data
from the ﬁrst 4 years of the DCCT exten-
sion study, the Epidemiology of Diabetes
Interventions and Complications (EDIC)
study. The EDIC has already shown the
long-term beneﬁcial effects of intensive
treatment on microvascular complica-
tions (4–6). Our goal was to establish
whether the follow-up study also un-
earths a longer-term relationship be-
tween glucose variability during the
DCCT and subsequent retinopathy and
nephropathy.
RESEARCH DESIGN AND
METHODS— We used the publicly
accessible datasets stored by the National
Institute of Diabetes and Digestive and
KidneyDiseases(NIDDK)relatingtoboth
theDCCTandtheﬁrst4yearsoftheEDIC
study.Afteranaverageperiodof6.5years
enrollment in the DCCT, patients were
offered intensive glucose management
and were asked to continue with
follow-up as part of the EDIC study (7).
Retinopathy development and pro-
gression was deﬁned as a 3-unit change
in the 25-point Early Treatment Diabetic
Retinopathy Study (ETDRS) score mea-
sured at baseline and in all patients com-
pleting year 4 in the EDIC (n  1,208), as
well as in a subset of patients at years 1
(n  369), 2 (n  447), and 3 (n  419).
Nephropathy was deﬁned as an albumin
excretion rate 40 mg/day.
A seven-point blood glucose proﬁle
was requested to be taken throughout the
dayatthreemonthlyintervalsduring,but
not beyond, the DCCT. Mean blood glu-
cose (area under the curve) and glucose
variability (SD and mean amplitude of
glycemic excursions [MAGE] [8]) during
the DCCT were calculated as published
previously (9). Results were virtually
identical for the blood glucose proﬁles
basedonﬁveormorereadingsandarenot
considered further.
Statistical methods
Weusedthegeneralizedestimatingequa-
tion with a logit link to assess the effect of
covariates on the odds of development or
progression of retinopathy and nephrop-
athyoverrepeatedtimepoints(10,11)us-
ing the Stata statistical computer package
(12). Wald robust estimates of SE were
used to estimate 95% CIs. The two treat-
ment groups (intensive versus conven-
tional) were analyzed separately and
combined. Models were adjusted as de-
scribed in Table 1.
RESULTS— Patients with a three-step
or more change in the ETDRS at years 1,
2,3,and4were15of369(4%),37of443
(8%), 47 of 419 (11%), and 146 of 1,208
(12%), respectively. A total of 115 of
1,343 (9%) patients had an ETDRS score
3 at EDIC baseline. Patients with ne-
phropathy (albumin excretion rate 40
mg/day) at years 3 and 4 were 184 of
1,302 (14%). The mean  SD variabil-
ity of glucose was 4.11  0.88 and
8.01  2.00 mmol/l for SD and MAGE,
respectively.
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between blood glucose variability in the
DCCT and the development or progres-
sion of retinopathy in EDIC after adjust-
ment (Table 1). Associations between
nephropathyandglycemiaweregenerally
less strong than those for retinopathy,
with the exception of A1C at eligibility.
Our focus has been on new events since
the end of the DCCT. A separate analysis
taking any event, irrespective of the time
of event, from the DCCT up to and in-
cluding the EDIC showed that there was
no signiﬁcant relationship with blood
glucose variability (data not shown).
CONCLUSIONS — This analysis has
extended the follow-up of DCCT patients
to year 4 of the EDIC study and found no
evidence, or even a signal, that this un-
covers a role for glucose variability in
adding to the risk of retinopathy and
nephropathy already predicted by the
mean glucose alone.
This ﬁnding is consistent with two
analyses of events in the DCCT alone,
which seemingly showed glucose vari-
ability to be of little relevance to compli-
cation risk (1,2). However, variations in
A1C (as opposed to glucose) around a
mean A1C value do indeed seem to pre-
dict small vessel complications, raising
the possibility either that long-term ﬂuc-
tuations in glycemia are more important
than short-term ones or that A1C was
more sensitive in detecting glycemic vari-
ability than the method used to assess
mean glucose in the DCCT (3). An addi-
tional observation is that A1C at the start
of the DCCT, which was a strong predic-
tor of retinopathy during the DCCT, was
not such a good predictor in this analysis
ofEDIC.Thismaybeanearlierindication
of the waning effect of metabolic memory
described recently in respect to the legacy
effect that A1C during the DCCT had on
retinopathy by year 10 of EDIC (13).
There are limitations to this study,
with the most important being the lack of
glucose proﬁling during EDIC and the in-
ability to precisely evaluate diurnal glyce-
mic variation from quarterly seven-point
glucose proﬁles. Regarding the ﬁrst limi-
tation, we determined this analysis
should regard glucose variability during
the DCCT as one of the baseline covari-
ates at the start of EDIC. With respect to
glycemic control throughout EDIC, we
have also accounted for A1C during the
extension study, and it is reassuring that
all patients were offered the same inten-
sive treatment during this period. Coun-
terbalancinganylimitationsarethesizeof
the DCCT/EDIC dataset (e.g., there was
more than 22,000 seven-point glucose
proﬁles during the DCCT) and the fact
thatthestudyis,inmanyrespects,impos-
sible to reproduce because it was
performed in an era when possible con-
founding factors, such as the use of anti-
hypertensive, antiplatelet, and lipid-
lowering agents, were not in routine use.
Insummary,increasingthefollow-up
periodofDCCTpatientstoyear4ofEDIC
hasnotunearthedanassociationbetween
glucose variability and microvascular
complicationriskthataddstothatalready
predicted by a patient’s mean glucose
value.
Acknowledgments— This research has been
supported by a project grant (BDA:RD07/
0003461) from Diabetes UK.
This research was also supported by an un-
restricted educational grant from Novo Nor-
disk. No other potential conﬂicts of interest
relevant to this article were reported.
Parts of this study were presented at the Di-
abetes UK Annual Professional Conference,
Glasgow, U.K., 11–13 March 2009.
Table 1—Longitudinal multiple logistic regression models for microvascular complications
Intensive Conventional Combined
Odds ratio (95% CI) P Odds ratio (95% CI) P Odds ratio (95% CI) P
Retinopathy
Model 1
A1C eligibility, DCCT 0.94 (0.76–1.16) 0.59 1.04 (0.90–1.21) 0.52 1.02 (0.90–1.15) 0.73
Mean BG, DCCT 1.31 (0.96–1.77) 0.08 1.32 (1.19–1.46) 0.001 1.31 (1.19–10.44) 0.001
MAGE, DCCT 1.03 (0.82–1.29) 0.27 0.92 (0.83–1.02) 0.15 0.96 (0.88–1.05) 0.45
Mean A1C, EDIC 1.66 (1.31–2.150) 0.001 1.29 (1.08–1.54) 0.004 1.41 (1.22–1.62) 0.001
Model 2
A1C eligibility, DCCT 0.94 (0.76–1.16) 0.59 1.04 (0.90–1.201) 0.5 1.02 (0.90–1.15) 0.11
Mean BG, DCCT 1.26 (0.90–1.76) 0.16 1.35 (1.21–1.49) 0.001 1.33 (1.21–1.51) 0.001
SDBG, DCCT 1.16 (0.69–1.93) 0.55 0.82 (0.65–1.03) 0.09 0.9 (0.74–1.10) 0.32
Mean A1C, EDIC 1.66 (1.31–2.11) 0.001 1.26 (1.06–1.51) 0.008 1.39 (1.20–1.60) 0.001
Nephropathy
Model 1
A1C eligibility, DCCT 1.31 (0.97–1.76) 0.07 1.35 (1.07–1.71) 0.011 1.33 (1.09–1.610) 0.003
Mean BG, DCCT 0.97 (0.62–1.52) 0.9 1.08 (0.93–1.26) 0.29 1.08 (0.93–1.24) 0.29
MAGE, DCCT 1.13 (0.90–1.43) 0.26 0.99 (0.86–1.15) 0.96 1.01 (0.89–1.14) 0.8
Mean A1C, EDIC 1.46 (1.11–1.91) 0.005 1.34 (1.02–1.76) 0.03 1.38 (1.13–1.67) 0.001
Model 2
A1C eligibility, DCCT 1.29 (0.96–1.73) 0.08 1.36 (1.07–1.71) 0.01 1.32 (1.09–1.60) 0.003
Mean BG, DCCT 1.08 (0.65–1.78) 0.75 1.1 (0.95–1.28) 0.17 1.11 (0.96–1.28) 0.14
SDBG, DCCT 0.99 (0.54–1.83) 0.99 0.83 (0.59–1.18) 0.31 0.86 (0.64–1.15) 0.31
Mean A1C, EDIC 1.44 (1.11–1.86) 0.005 1.33 (1.01–1.76) 0.037 1.38 (1.13–1.67) 0.001
Modelsadjustedforage(EDICbaseline),diseaseduration(EDICbaseline),andsex.RetinopathymodelsfurtheradjustedforlasertherapyinDCCT,andnephropathy
further adjusted for patients with microalbuminuria at the DCCT closeout. Example interpretation: A1C odds ratio represents proportionate change per 1% unit
difference in A1C. BG, blood glucose; SDBG, SD of blood glucose.
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